Table 3. Cumulative risk of ALL relapse... | American Society of Hematology

Table 3.

Cumulative risk of ALL relapse according to CASP8AP2 expression in relation to that of other selected clinical and biologic variables

		95% Cl of hazard ratio
Variable	Hazard ratio	Lower	Upper	P
CASP8AP2 expression
Low vs high*	7.98‡	1.45	43.83	.017
Log-transformed signal†	6.32‡	1.83	21.79	.004
Age, y
Younger than 1 vs 1 to 10	5.63	0.71	44.61	.100
Older than 10 vs 1 to 10	10.33‡	3.00	35.61	<.001
WBC, × 10⁹/L
More than 10 to 49 vs 10 or less	0.86	0.22	3.38	.830
50 to 99 vs 10 or less	2.72	0.50	14.72	.240
100 or more vs 10 or less	4.15	0.95	18.22	.059
Genotype (B-lineage only)
BCR-ABL vs other	6.45‡	1.69	24.65	.001
E2A-PBX vs other	0.96	0.26	3.47	.940
MLL-AF4 vs other	1.70	0.54	5.38	.370
TEL-AML1 vs other	5.18	0.96	27.92	.056
Hyperdiploidy vs other	0.37	0.03	4.62	.440
Lineage
T vs B	6.12‡	1.58	23.78	.009

		95% Cl of hazard ratio
Variable	Hazard ratio	Lower	Upper	P
CASP8AP2 expression
Low vs high*	7.98‡	1.45	43.83	.017
Log-transformed signal†	6.32‡	1.83	21.79	.004
Age, y
Younger than 1 vs 1 to 10	5.63	0.71	44.61	.100
Older than 10 vs 1 to 10	10.33‡	3.00	35.61	<.001
WBC, × 10⁹/L
More than 10 to 49 vs 10 or less	0.86	0.22	3.38	.830
50 to 99 vs 10 or less	2.72	0.50	14.72	.240
100 or more vs 10 or less	4.15	0.95	18.22	.059
Genotype (B-lineage only)
BCR-ABL vs other	6.45‡	1.69	24.65	.001
E2A-PBX vs other	0.96	0.26	3.47	.940
MLL-AF4 vs other	1.70	0.54	5.38	.370
TEL-AML1 vs other	5.18	0.96	27.92	.056
Hyperdiploidy vs other	0.37	0.03	4.62	.440
Lineage
T vs B	6.12‡	1.58	23.78	.009

Analyzed using Fine and Gray's estimator.³⁵

Comparisons of relapse hazards for 33 patients with the lowest levels of CASP8AP2 expression versus the 33 patients with the highest levels.

Increase of risk per unit decrease in log CASP8AP2 expression.